CloneID: rec-RC-IgG
Antigen Long Description: The original antibody was isolated from circulating blood plasmablast of a 59-year-old VZV-seropositive man recently immunized with zoster vaccine Zostavax.
Origin Pub PMID: 23077312
Buffer Composition: PBS with 0.02% Proclin 300.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: Q775J3; Q9J3N1
Specificity Statement: This antibody targets the domain IV region of envelope glycoprotein B of the Varicella zoster virus (VZV) also known as the human herpesvirus 3 (HHV-3, HHV3) or Human alpha herpesvirus 3. This DNA virus from the herpes virus group can infect humans causing chickenpox in children and shingles (herpes zoster) in adults. Varicella is characterized by a maculopapular, vesicular rash that can be pruritic and evolves into dried crusts (scabs) over a 3- to 7-day period. Chicken pox is considered contagious beginning 1-2 days before rash onset until all lesions have crusted (scabbed).
Application Notes (Clone): This antibody was used for the immunohistochemical staining of fixed and unfixed VZV-infected and control human lung fibroblast cells. This antibody was also reported to neutralize VZV infection in a plaque reduction assay. The concentration of IgG that produced 50% plaque reduction was 0.6 μg/ml. This antibody was also used for the immunoprecipitation of VZV-infected cells (PMID: 23077312).
Deutsch
English
